Combined gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer.
- Author:
Li-ping WANG
1
;
Qi-da MEI
;
Guo-qian GAO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; Cisplatin; administration & dosage; adverse effects; Deoxycytidine; administration & dosage; adverse effects; analogs & derivatives; Female; Humans; Lung Neoplasms; drug therapy; Male; Middle Aged
- From: Chinese Journal of Oncology 2003;25(6):590-591
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical efficacy and side effects of advanced non-small cell lung cancer (NSCLC) treated by combined gemcitabine and cisplatin.
METHODSForty-six patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC were alloted to the study. The patients received gemcitabine 1 000 mg/m(2) on D 1, 8, and cisplatin 80 mg on D 1 approximately 3 in the 21-day cycle.
RESULTSAn objective response was obtained in 46% (21/46) of patients (1 CR and 21 PR), whereas 19 patients had stable disease and 6 patients showed progressive disease. The response rate was 58.3% in untreated patients and 31.8% was obtained in treated ones. Significant difference was observed between the two groups (P < 0.05). The main toxicities were leukopenia and thrombocytopenia.
CONCLUSIONThe combination of gemcitabine and cisplatin, being feasible and well-tolerated, should be taken as an energetic scheme in the treatment of advanced NSCLC.
